8-K: TC BioPharm Announces Shareholder Update, Highlights Cost Savings and Upcoming Milestones

TC BioPharm provided a shareholder update, highlighting approximately $11.6 million in cost savings and key milestones including FDA clearance for a Phase 1B AML study.

Summary

• TC BioPharm issued a shareholder update on February 14, 2024, detailing achievements and future plans.
• The company highlighted approximately $11.6 million in cost savings through streamlining efficiencies and asset prioritization.
• TC BioPharm received FDA clearance for an investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML).
• A new collaboration with Queen Mary University of London will expand their TCB-008 therapy into anti-fungal and anti-bacterial diseases, with non-dilutive funding.
• The company completed the ACHIEVE Study safety cohort and received a positive review from the Data Safety Monitoring Board (DSMB).
• A preliminary proxy statement was filed on February 9, 2024, regarding a potential issuance of Ordinary Shares or ADSs, requiring shareholder approval.
• The company is transitioning from a foreign filer to a domestic filer status for SEC reporting and NASDAQ compliance.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant achievements in cost savings, regulatory approvals, and strategic partnerships. However, the potential share issuance introduces some uncertainty and risk.

Positives

• The company has achieved significant cost savings of approximately $11.6 million.
• FDA clearance for the Phase 1B AML study is a major regulatory milestone.
• The collaboration with Queen Mary University of London diversifies the application of their TCB-008 therapy.
• The completion of the ACHIEVE Study safety cohort and positive DSMB review indicates progress in clinical trials.
• The company is actively pursuing strategic partnerships and collaborations.

Negatives

• The company is seeking shareholder approval for a potential share issuance, which could dilute existing shareholders.
• The terms and conditions of any potential financing have not yet been determined.

Risks

• The proposed share issuance may not be approved by shareholders.
• The company's ability to execute on its M&A or capital raising strategy is not guaranteed.
• The company's actual results may differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company aims to make further progress in its pipeline of gamma delta T cell therapies, focusing on strategic partnerships and collaborations, and expects to receive interim data for the ACHIEVE trial in 2024. They also plan to expand their platform with proof of concept and preclinical work for their anti-fungal/anti-bacterial program.

Management Comments

• Bryan Kobel, Chief Executive Officer, stated that the previous year was a time of significant operational achievement.
• Kobel also mentioned that the company is confident in TCB-008 as a therapeutic.
• Kobel noted that the company aims to make additional strides throughout their pipeline via a strategic and disciplined approach in 2024.
• Kobel highlighted that receiving FDA clearance for TCB-008 in AML is an important milestone.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on cell therapies and oncology. The company's progress in clinical trials and regulatory approvals is a positive sign for its potential in the competitive landscape of cancer treatments. The expansion into non-oncology indications also positions the company to address a broader range of diseases.

Comparison to Industry Standards

• TC BioPharm's focus on gamma-delta T cell therapies places it in a niche area of the cell therapy market, with competitors like Adaptimmune and Atara Biotherapeutics focusing on different T cell approaches.
• The $11.6 million cost savings is a significant achievement, as many biotech companies struggle with high operating costs during clinical development.
• The FDA clearance for a Phase 1B study is a key milestone, comparable to other companies advancing their therapies through clinical trials.
• The collaboration with Queen Mary University of London is a strategic move to expand the application of their technology, similar to other biotech companies seeking partnerships to broaden their reach.

Stakeholder Impact

• Shareholders may experience dilution if the proposed share issuance is approved.
• Employees may benefit from the company's cost-saving measures and strategic growth.
• Customers (patients) may benefit from the advancement of new therapies.
• The company's financial health may improve due to cost savings and potential capital raising.

Next Steps

• The company will seek shareholder approval for the proposed share issuance.
• The company will continue to advance its clinical trials, including the ACHIEVE trial.
• The company will focus on strategic partnerships and collaborations.
• The company will continue to develop its anti-fungal/anti-bacterial program.

Key Dates

Keywords

TC BioPharm, Gamma-delta T cell therapy, Acute Myeloid Leukemia, AML, FDA clearance, Shareholder update, Cost savings, Clinical trials, Proxy statement, Capital raise, TCB-008, Queen Mary University of London, Non-dilutive funding